Wedbush Raises Price Target for Scholar Rock (NASDAQ: SRRK) Ahead of Key FDA Decision

Font: Financial Modeling Prep  • Aug 21, 2026

• Analyst firm Wedbush has increased its price target for Scholar Rock (NASDAQ: SRRK) to $64.00, maintaining an "Outperform" rating for the biopharmaceutical stock.
• A key catalyst for the company is the upcoming U.S. Food and Drug Administration (FDA) decision on September 30 for its investigational spinal muscular atrophy (SMA) treatment, apitegromab.
• Scholar Rock has made significant regulatory and manufacturing progress, positioning apitegromab as a potential first-in-class muscle-targeted therapy for SMA, highlighting strong operational management.

Analyst firm Wedbush shows confidence in Scholar Rock, raising its price target to $64.00 from a previous target of $58.00. Scholar Rock is a biopharmaceutical company developing treatments for serious diseases like spinal muscular atrophy (SMA). The firm also maintains its "Outperform" rating for Scholar Rock, which was trading at $56.29 when the rating was published.

This positive outlook is connected to a significant upcoming event for Scholar Rock. The company awaits a U.S. Food and Drug Administration (FDA) decision on September 30 for its investigational SMA treatment, apitegromab. This follows a resubmitted biologics license application, which is a formal request to approve a new drug for sale, marking a critical milestone in the drug approval process.

Apitegromab could become the first muscle-targeted therapy for both children and adults with SMA. As highlighted by MarketBeat, CEO David Hallal stated it is the first myostatin inhibitor to show success in a Phase III trial. Myostatin is a protein that naturally limits muscle growth, so blocking it may help patients build muscle, offering a novel therapeutic approach.

In preparation, Scholar Rock has made regulatory progress. As reported by Business Wire, the company successfully removed a commercial facility from its application and is now supported by an alternate manufacturing facility. This update applies to its regulatory filings in the U.S., Europe, and Japan, showing active management of its global strategy and supply chain.

Currently, Scholar Rock trades at a price of $55.87, with a 52-week range between $27.07 and $58.49. The company has a market capitalization, or total stock value, of approximately $6.69 billion. The daily trading volume is around 503,255 shares, reflecting investor interest in this biotech stock.